Page 15 - Adjuvant Treatment News Today : Breaking News, Live Updates & Top Stories | Vimarsana

LYNPARZA® (olaparib) approved in the US as adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer

WILMINGTON, Del. (BUSINESS WIRE) Mar 11, 2022

United statesUnited kingdomCity ofDave fredricksonJessica mcduellDaiichi sankyoAndrew tuttBrendan mcevoyRoy baynesKing college londonBreast cancer researchMerck research laboratoriesAmerican society of clinical oncologyUnion for international cancerDrug administrationUs national cancer institute

LYNPARZA® (olaparib) approved in the US as adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer

Press release content from Business Wire. The AP news staff was not involved in its creation.

United statesCity ofUnited kingdomDave fredricksonAndrew tuttRoy baynesKing college londonMerck research laboratoriesAmerican society of clinical oncologyDrug administrationUs national cancer instituteFrontier science technology research foundationBreast international groupMerck co incInstitute of cancer researchHead of global clinical development

FDA Approves LYNPARZA® (olaparib) as Adjuvant Treatment for Patients With Germline BRCA-Mutated (gBR

First and Only Targeted Adjuvant Therapy With FDA-Approved Indication Specifically for Patients With gBRCAm, HER2-Negative High-Risk Early Breast CancerFirst and Only PARP Inhibitor to Show Overall Survival Benefit in Early Breast CancerKENILWORTH, N.J. (BUSINESS WIRE) $MRK #MRK AstraZeneca and Merck (NYSE: MRK),.

United statesUnited kingdomCity ofDave fredricksonChrissy trankPeter dannenbaumAndrew tuttDamini chokshiRoy baynesMelissa moodyKing college londonMerck research laboratoriesDrug administrationFrontier science technology research foundationBreast international groupAmerican society of clinical oncology annual meeting

Investegate |NOVARTIS AG CHF0 50(REGD) Announcements | NOVARTIS AG CHF0 50(REGD): New Kisqali® data shows consistent overall survival benefit across genomic and clinical subtypes of interest in HR+/HER2- metastatic breast cancer

Investegate |NOVARTIS AG CHF0 50(REGD) Announcements | NOVARTIS AG CHF0 50(REGD): New Kisqali® data shows consistent overall survival benefit across genomic and clinical subtypes of interest in HR+/HER2- metastatic breast cancer
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

San antonioUnited statesNew jerseyComunidad autonoma de catalunaEast hanoverIsabella zinckThomas hungerbuehlerSusanne schaffertAshley bufordClin oncSamir shahParag mahantiJulie masowSloan simpsonAleix pratAlina levchuk

Novartis Pharma AG: New Kisqali data shows consistent overall survival benefit across genomic and clinical subtypes of interest in HR+/HER2- metastatic breast cancer

Data from the MONALEESA Phase III program provide further evidence of the unique profile of Kisqali, the CDK4/6 inhibitor with the longest reported median overall survival (OS) in HR+/HER2- metastatic

San antonioUnited statesNew jerseyComunidad autonoma de catalunaEast hanoverIsabella zinckThomas hungerbuehlerSusanne schaffertAshley bufordClin oncSamir shahParag mahantiJulie masowSloan simpsonAleix pratAlina levchuk